The month ahead: June’s upcoming events
Crunch time approaches for UroGen.
Crunch time approaches for UroGen.
GSK and iTeos dump belrestotug, with the latter now looking at “strategic alternatives”.
Conference activity picks up, with the big one – ASCO – at the end of the month.
The CAPItello-280 castrate-resistant prostate cancer trial is discontinued early.
The curtain lifts on Veritac-2, rusfertide, and another double plenary for Astra.
Gilead’s TROP2 ADC prevails in Ascent-04, in first-line PD-L1-positive TNBC.